Brain natriuretic peptide
EstablishedBNP/NT-proBNP is the primary blood marker for diagnosing and staging heart failure.
BNP is a heart hormone that rises when the heart is under strain, helping doctors diagnose and grade heart failure. The "normal" cutoff isn't one-size-fits-all — it should probably be adjusted for age, and it reads falsely low in patients with obesity.
Brain natriuretic peptide (BNP) and its precursor fragment NT-proBNP are hormones released by the heart ventricles in response to wall stress, serving as the primary blood biomarkers for diagnosing and staging heart failure.
Elevated BNP/NT-proBNP supports a heart failure diagnosis in a patient with dyspnea, with higher levels correlating with disease severity; levels are also used for risk stratification and monitoring treatment response.
Guideline cutoffs vary: NICE recommends >400 ng/L (NT-proBNP) and ESC recommends >125 ng/L for outpatient workup. Current research (2024-2025) argues for age-adjusted thresholds, since levels naturally rise with age, and levels run lower in patients with obesity, which can mask heart failure under a universal cutoff.
BNP/NT-proBNP guides decisions about hospitalization/discharge and identifies patients at higher risk for cardiovascular events; levels are also used to differentiate cardiac from non-cardiac causes of shortness of breath in the emergency department.
Widely used cutoffs may need age- and BMI-adjustment for optimal accuracy per current research.
- Berthelot, E., et al. (2024). Setting the optimal threshold of NT-proBNP and BNP for the diagnosis of heart failure in patients over 75 years. PMC.
- JACC. (2021). NT-proBNP for Risk Prediction in Heart Failure: Optimal Cutoffs Across BMI Categories.